{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:52:56Z","timestamp":1790977976978,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08237-6","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:12:41Z","timestamp":1790928761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Denosumab\u2014efficacy, safety, persistence and sequential strategies\u2014a systematic review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6740-3072","authenticated-orcid":false,"given":"Natasha Amran","family":"Laursen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"S\u00f8lling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Harsl\u00f8f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente L.","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"4","key":"8237_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s001980050224","volume":"10","author":"HK Genant","year":"1999","unstructured":"Genant HK, Cooper C, Poor G et al (1999) Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10(4):259\u2013264. https:\/\/doi.org\/10.1007\/s001980050224","journal-title":"Osteoporos Int"},{"key":"8237_CR2","unstructured":"Kanis J (2007) Assessment of osteoporosis at the primary health-care level. 2007. WHO Scientific Group Technical Report"},{"key":"8237_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/tcrm.S72456","volume":"10","author":"AS Nazrun","year":"2014","unstructured":"Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN (2014) A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag 10:937\u2013948. https:\/\/doi.org\/10.2147\/tcrm.S72456","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"8237_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","volume":"148","author":"C MacLean","year":"2008","unstructured":"MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148(3):197\u2013213. https:\/\/doi.org\/10.7326\/0003-4819-148-3-200802050-00198","journal-title":"Ann Intern Med"},{"issue":"12","key":"8237_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pr 66(12):1139\u20131146. https:\/\/doi.org\/10.1111\/ijcp.12022","journal-title":"Int J Clin Pr"},{"issue":"8","key":"8237_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821\u2013831. https:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"N Engl J Med"},{"issue":"1","key":"8237_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24(1):153\u2013161. https:\/\/doi.org\/10.1359\/jbmr.0809010","journal-title":"J Bone Miner Res"},{"issue":"4","key":"8237_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"8237_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"7","key":"8237_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diab Endocrinol 5(7):513\u2013523. https:\/\/doi.org\/10.1016\/s2213-8587(17)30138-9","journal-title":"Lancet Diab Endocrinol"},{"issue":"3","key":"8237_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00198-019-05228-8","volume":"31","author":"J Morley","year":"2020","unstructured":"Morley J, Moayyeri A, Ali L et al (2020) Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int 31(3):533\u2013545. https:\/\/doi.org\/10.1007\/s00198-019-05228-8","journal-title":"Osteoporos Int"},{"issue":"5","key":"8237_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28(5):1723\u20131732. https:\/\/doi.org\/10.1007\/s00198-017-3919-1","journal-title":"Osteoporos Int"},{"issue":"1","key":"8237_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","volume":"103","author":"AW Popp","year":"2018","unstructured":"Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K (2018) Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int 103(1):50\u201354. https:\/\/doi.org\/10.1007\/s00223-018-0394-4","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"8237_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Min Res 33(2):190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Min Res"},{"key":"8237_CR15","doi-asserted-by":"publisher","unstructured":"Tsourdi E, Zillikens MC, Meier C, et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab https:\/\/doi.org\/10.1210\/clinem\/dgaa756","DOI":"10.1210\/clinem\/dgaa756"},{"issue":"6","key":"8237_CR16","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","volume":"93","author":"HG Bone","year":"2008","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93(6):2149\u20132157. https:\/\/doi.org\/10.1210\/jc.2007-2814","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"8237_CR17","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T et al (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99(7):2599\u20132607. https:\/\/doi.org\/10.1210\/jc.2013-4175","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"8237_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbj\u00e6rg CS, Ho PR et al (2015) A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 100(4):1335\u20131342. https:\/\/doi.org\/10.1210\/jc.2014-4079","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"8237_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jgs.19260","volume":"73","author":"SL Greenspan","year":"2025","unstructured":"Greenspan SL, Perera S, Haeri NS, Nace DA, Resnick NM (2025) Denosumab for osteoporosis in older adults in long-term care: a randomized trial. J Am Geriatr Soc 73(2):445\u2013457. https:\/\/doi.org\/10.1111\/jgs.19260","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"8237_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL et al (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25(1):72\u201381. https:\/\/doi.org\/10.1359\/jbmr.090716","journal-title":"J Bone Miner Res"},{"key":"8237_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354. https:\/\/doi.org\/10.1016\/j.bone.2013.10.006","journal-title":"Bone"},{"issue":"6","key":"8237_CR22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121(6):1291\u20131299. https:\/\/doi.org\/10.1097\/AOG.0b013e318291718c","journal-title":"Obstet Gynecol"},{"issue":"8","key":"8237_CR23","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101(8):3163\u20133170. https:\/\/doi.org\/10.1210\/jc.2016-1801","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8237_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05187-7","volume":"15","author":"Y Sobue","year":"2025","unstructured":"Sobue Y, Kosugiyama H, Asai S et al (2025) A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis. Sci Rep 15(1):22441. https:\/\/doi.org\/10.1038\/s41598-025-05187-7","journal-title":"Sci Rep"},{"issue":"9886","key":"8237_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886):50\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(13)60856-9","journal-title":"Lancet"},{"issue":"5","key":"8237_CR26","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2014) Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 99(5):1694\u20131700. https:\/\/doi.org\/10.1210\/jc.2013-4440","journal-title":"J Clin Endocrinol Metab"},{"key":"8237_CR27","unstructured":"Lin K ACP Updates Clinical Recommendations on Treatment of Osteoporosis. https:\/\/www.aafp.org\/pubs\/afp\/afp-community-blog\/entry\/acp-updates-clinical-recommendations-on-treatment-of-osteoporosis.html"},{"key":"8237_CR28","unstructured":"Osteoporosis management and fracture prevention in post-menopausal women and men > 50 years of age. https:\/\/www.racgp.org.au\/clinical-resources\/clinical-guidelines\/key-racgp-guidelines\/view-all-racgp-guidelines\/osteoporosis\/pharmacologic-approaches-to-prevention\/romosozumab"},{"key":"8237_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bonr.2018.03.006","volume":"8","author":"T Suzuki","year":"2018","unstructured":"Suzuki T, Nakamura Y, Kamimura M, Kato H (2018) Denosumab significantly improves lumbar spine bone mineral density more in treatment-na\u00efve than in long-term bisphosphonate-treated patients. Bone Rep 8:110\u2013114. https:\/\/doi.org\/10.1016\/j.bonr.2018.03.006","journal-title":"Bone Rep"},{"key":"8237_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8738959","volume":"2016","author":"A S\u00e1nchez","year":"2016","unstructured":"S\u00e1nchez A, Brun LR, Salerni H et al (2016) Effect of denosumab on bone mineral density and markers of bone turnover among postmenopausal women with osteoporosis. J Osteoporos 2016:8738959","journal-title":"J Osteoporos"},{"issue":"10","key":"8237_CR31","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","volume":"64","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Efstathiadou ZA et al (2015) Denosumab in treatment-na\u00efve and pre-treated with zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers. Metabolism 64(10):1291\u20131297. https:\/\/doi.org\/10.1016\/j.metabol.2015.06.018","journal-title":"Metabolism"},{"key":"8237_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bone.2018.10.001","volume":"120","author":"E Tsourdi","year":"2019","unstructured":"Tsourdi E, Makras P, Rachner TD et al (2019) Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone 120:44\u201349. https:\/\/doi.org\/10.1016\/j.bone.2018.10.001","journal-title":"Bone"},{"issue":"1","key":"8237_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health Jan-Feb 11(1):44\u201347. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00213.x","journal-title":"Value Health Jan-Feb"},{"issue":"10","key":"8237_CR34","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","volume":"26","author":"P Hadji","year":"2015","unstructured":"Hadji P, Papaioannou N, Gielen E et al (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 26(10):2479\u20132489. https:\/\/doi.org\/10.1007\/s00198-015-3164-4 2015\/10\/01","journal-title":"Osteoporos Int"},{"issue":"6","key":"8237_CR35","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","volume":"22","author":"DL Kendler","year":"2011","unstructured":"Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22(6):1725\u20131735. https:\/\/doi.org\/10.1007\/s00198-010-1378-z","journal-title":"Osteoporos Int"},{"issue":"1","key":"8237_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0351-2","volume":"12","author":"A Fahrleitner-Pammer","year":"2017","unstructured":"Fahrleitner-Pammer A, Papaioannou N, Gielen E et al (2017) Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos 12(1):58. https:\/\/doi.org\/10.1007\/s11657-017-0351-2","journal-title":"Arch Osteoporos"},{"key":"8237_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115890","volume":"146","author":"K Briot","year":"2021","unstructured":"Briot K, Schott A-M, Sanchez J-P, Chauny J-V, Samama P, D\u00e9sam\u00e9ricq G (2021) High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: a prospective cohort study. Bone 146:115890. https:\/\/doi.org\/10.1016\/j.bone.2021.115890","journal-title":"Bone"},{"issue":"1","key":"8237_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-018-0491-z","volume":"13","author":"SL Silverman","year":"2018","unstructured":"Silverman SL, Siris E, Belazi D et al (2018) Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Arch Osteoporos 13(1):85. https:\/\/doi.org\/10.1007\/s11657-018-0491-z","journal-title":"Arch Osteoporos"},{"issue":"12","key":"8237_CR39","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s40618-017-0701-3","volume":"40","author":"S Migliaccio","year":"2017","unstructured":"Migliaccio S, Francomano D, Romagnoli E et al (2017) Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. J Endocrinol Investig 40(12):1321\u20131326. https:\/\/doi.org\/10.1007\/s40618-017-0701-3","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"8237_CR40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/14397595.2020.1789319","volume":"31","author":"M Nakayama","year":"2021","unstructured":"Nakayama M, Furuya T, Inoue E et al (2021) Adherence to denosumab for the treatment of osteoporosis in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study. Mod Rheumatol 31(2):510\u2013513. https:\/\/doi.org\/10.1080\/14397595.2020.1789319","journal-title":"Mod Rheumatol"},{"issue":"10","key":"8237_CR41","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00198-016-3623-6","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Kyvernitakis I, Kann PH et al (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27(10):2967\u20132978. https:\/\/doi.org\/10.1007\/s00198-016-3623-6","journal-title":"Osteoporos Int"},{"issue":"10","key":"8237_CR42","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","volume":"26","author":"L Karlsson","year":"2015","unstructured":"Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Str\u00f6m O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401\u20132411. https:\/\/doi.org\/10.1007\/s00198-015-3253-4","journal-title":"Osteoporos Int"},{"issue":"4","key":"8237_CR43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.31616\/asj.2019.0230","volume":"14","author":"K Kobayashi","year":"2020","unstructured":"Kobayashi K, Ando k, machino m et al (2020) persistence of Denosumab Therapy among Patients with Osteoporosis. Asian Spine J 14(4):453\u2013458. https:\/\/doi.org\/10.31616\/asj.2019.0230","journal-title":"Asian Spine J"},{"issue":"9","key":"8237_CR44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.18553\/jmcp.2015.21.9.824","volume":"21","author":"L-I Cheng","year":"2015","unstructured":"Cheng L-I, Durden E, Limone B et al (2015) Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm 21(9):824\u2013833. https:\/\/doi.org\/10.18553\/jmcp.2015.21.9.824","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"8237_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12(1):22. https:\/\/doi.org\/10.1007\/s11657-017-0316-5","journal-title":"Arch Osteoporos"},{"issue":"10","key":"8237_CR46","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00198-017-4144-7","volume":"28","author":"C Reyes","year":"2017","unstructured":"Reyes C, Tebe C, Martinez-Laguna D et al (2017) One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int 28(10):2997\u20133004. https:\/\/doi.org\/10.1007\/s00198-017-4144-7","journal-title":"Osteoporos Int"},{"issue":"9","key":"8237_CR47","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00198-019-05051-1","volume":"30","author":"JK Ban","year":"2019","unstructured":"Ban JK, Hao BB, McCarthy L, Guilcher SJT, Cadarette SM (2019) Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap. Osteoporos Int 30(9):1865\u20131872. https:\/\/doi.org\/10.1007\/s00198-019-05051-1","journal-title":"Osteoporos Int"},{"issue":"1","key":"8237_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0413-5","volume":"13","author":"T Petranova","year":"2017","unstructured":"Petranova T, Boyanov M, Shinkov A, Petkova R, Intorcia M, Psachoulia E (2017) Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates. Arch Osteoporos 13(1):1. https:\/\/doi.org\/10.1007\/s11657-017-0413-5","journal-title":"Arch Osteoporos"},{"key":"8237_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115838","volume":"144","author":"A Delbar","year":"2021","unstructured":"Delbar A, Pflimlin A, Delabri\u00e8re I et al (2021) Persistence with osteoporosis treatment in patients from the Lille University Hospital Fracture Liaison Service. Bone 144:115838. https:\/\/doi.org\/10.1016\/j.bone.2020.115838","journal-title":"Bone"},{"issue":"9","key":"8237_CR50","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1185\/03007995.2015.1065241","volume":"31","author":"L Fuksa","year":"2015","unstructured":"Fuksa L, Vytrisalova M (2015) Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic. Curr Med Res Opin 31(9):1645\u20131653. https:\/\/doi.org\/10.1185\/03007995.2015.1065241","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"8237_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-023-01210-4","volume":"18","author":"AB Pedersen","year":"2023","unstructured":"Pedersen AB, Risbo N, Kafatos G, Neasham D, O\u2019Kelly J, Ehrenstein V (2023) Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study. Arch Osteoporos 18(1):19. https:\/\/doi.org\/10.1007\/s11657-023-01210-4","journal-title":"Arch Osteoporos"},{"issue":"1","key":"8237_CR52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40744-021-00282-3","volume":"8","author":"S Monov","year":"2021","unstructured":"Monov S, Nestorova R, Velkova M et al (2021) Persistence with denosumab in women at high risk of fracture in Bulgaria. Rheumatol Ther 8(1):443\u2013455. https:\/\/doi.org\/10.1007\/s40744-021-00282-3","journal-title":"Rheumatol Ther"},{"issue":"11","key":"8237_CR53","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/jcph.738","volume":"56","author":"A Eliasaf","year":"2016","unstructured":"Eliasaf A, Amitai A, Maram Edry M, Yosselson Superstine S, Rotman Pikielny P (2016) Compliance, persistence, and preferences regarding osteoporosis treatment during active therapy or drug holiday. J Clin Pharmacol 56(11):1416\u20131422. https:\/\/doi.org\/10.1002\/jcph.738","journal-title":"J Clin Pharmacol"},{"key":"8237_CR54","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.jfma.2023.05.022","volume":"122","author":"C-C Lee","year":"2023","unstructured":"Lee C-C, Fu S-H, Chen H-M et al (2023) The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: visualize the gap between reality and expectations. J Formos Med Assoc 122:S55\u2013S64. https:\/\/doi.org\/10.1016\/j.jfma.2023.05.022","journal-title":"J Formos Med Assoc"},{"key":"8237_CR55","doi-asserted-by":"publisher","unstructured":"Hayes KN, Sendhil SR, Aggarwal S, et al (2025) Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States. JBMR Plus 9(6). https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf061","DOI":"10.1093\/jbmrpl\/ziaf061"},{"issue":"1","key":"8237_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-016-0282-3","volume":"11","author":"\u00c9 Tremblay","year":"2016","unstructured":"Tremblay \u00c9, Perreault S, Dorais M (2016) Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos 11(1):30. https:\/\/doi.org\/10.1007\/s11657-016-0282-3","journal-title":"Arch Osteoporos"},{"issue":"2","key":"8237_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy AK et al (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31(2):125\u2013136. https:\/\/doi.org\/10.1007\/s10654-016-0117-y","journal-title":"Eur J Epidemiol"},{"key":"8237_CR58","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/clep.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449\u2013490. https:\/\/doi.org\/10.2147\/clep.S91125","journal-title":"Clin Epidemiol"},{"issue":"7","key":"8237_CR59","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00198-019-04963-2","volume":"30","author":"DM Borek","year":"2019","unstructured":"Borek DM, Smith RC, Gruber CN, Gruber BL (2019) Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study. Osteoporos Int 30(7):1455\u20131464. https:\/\/doi.org\/10.1007\/s00198-019-04963-2","journal-title":"Osteoporos Int"},{"issue":"1","key":"8237_CR60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00198-021-06102-2","volume":"33","author":"E Boschitsch","year":"2022","unstructured":"Boschitsch E, Naegele O, Klinger A, Brix-Samoylenko H (2022) Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis. Osteoporos Int 33(1):263\u2013272. https:\/\/doi.org\/10.1007\/s00198-021-06102-2","journal-title":"Osteoporos Int"},{"issue":"1","key":"8237_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00932-7","volume":"16","author":"ME Walsh","year":"2021","unstructured":"Walsh ME, Fahey T, Moriarty F (2021) Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland. Arch Osteoporos 16(1):71. https:\/\/doi.org\/10.1007\/s11657-021-00932-7","journal-title":"Arch Osteoporos"},{"issue":"6","key":"8237_CR62","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38(6):922\u2013928. https:\/\/doi.org\/10.1016\/j.bone.2005.10.022","journal-title":"Bone"},{"issue":"10","key":"8237_CR63","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Min Res 39(10):1393\u20131405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Min Res"},{"issue":"2","key":"8237_CR64","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1210\/clinem\/dgaf614","volume":"111","author":"BL Langdahl","year":"2026","unstructured":"Langdahl BL, Laursen NA, M\u00e4kinen V, Harsl\u00f8f T, S\u00f8lling AS (2026) Approach to the patient - transitions in osteoporosis therapy. J Clin Endocrinol Metab 111(2):e577\u2013e585. https:\/\/doi.org\/10.1210\/clinem\/dgaf614","journal-title":"J Clin Endocrinol Metab"},{"key":"8237_CR65","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2147\/rmhp.S426869","volume":"16","author":"AR Abduelkarem","year":"2023","unstructured":"Abduelkarem AR, Guella A, Hamrouni AM, Hassanein MM, Nasr A, Rana O (2023) Denosumab use in chronic kidney disease associated osteoporosis: a narrative review. Risk Manag Health Policy 16:1809\u20131813. https:\/\/doi.org\/10.2147\/rmhp.S426869","journal-title":"Risk Manag Health Policy"},{"issue":"12","key":"8237_CR66","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30(12):2437\u20132448. https:\/\/doi.org\/10.1007\/s00198-019-05146-9","journal-title":"Osteoporos Int"},{"issue":"1","key":"8237_CR67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"HK Genant","year":"2017","unstructured":"Genant HK, Engelke K, Bolognese MA et al (2017) Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32(1):181\u2013187. https:\/\/doi.org\/10.1002\/jbmr.2932","journal-title":"J Bone Miner Res"},{"key":"8237_CR68","doi-asserted-by":"publisher","unstructured":"McClung MR, Bolognese MA, Brown JP, et al (2021) Skeletal responses to romosozumab after 12 months of denosumab. JBMR Plus 5(7) https:\/\/doi.org\/10.1002\/jbm4.10512","DOI":"10.1002\/jbm4.10512"},{"issue":"2","key":"8237_CR69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jbmr\/zjae179","volume":"40","author":"N Hong","year":"2024","unstructured":"Hong N, Shin S, Kim H, Cho SJ, Park JA, Rhee Y (2024) Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women. J Bone Miner Res 40(2):184\u2013192. https:\/\/doi.org\/10.1093\/jbmr\/zjae179","journal-title":"J Bone Miner Res"},{"issue":"9999","key":"8237_CR70","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147\u20131155. https:\/\/doi.org\/10.1016\/s0140-6736(15)61120-5","journal-title":"Lancet"},{"issue":"7","key":"8237_CR71","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4158\/ep-2019-0596","volume":"26","author":"F Cosman","year":"2020","unstructured":"Cosman F (2020) Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture. Endocr Pract 26(7):777\u2013786. https:\/\/doi.org\/10.4158\/ep-2019-0596","journal-title":"Endocr Pract"},{"issue":"2","key":"8237_CR72","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Min Res 32(2):198\u2013202. https:\/\/doi.org\/10.1002\/jbmr.3051","journal-title":"J Bone Min Res"},{"issue":"9","key":"8237_CR73","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/jbmr\/zjae116","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Oates M, Betah D et al (2024) Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Miner Res 39(9):1268\u20131277. https:\/\/doi.org\/10.1093\/jbmr\/zjae116","journal-title":"J Bone Miner Res"},{"issue":"16","key":"8237_CR74","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"3","key":"8237_CR75","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M et al (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Min Res 34(3):419\u2013428. https:\/\/doi.org\/10.1002\/jbmr.3622","journal-title":"J Bone Min Res"},{"key":"8237_CR76","doi-asserted-by":"publisher","unstructured":"Leder BZ, Ramchand SK, Jordan M, et al (2026) 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol https:\/\/doi.org\/10.1016\/s2213-8587(25)00319-5","DOI":"10.1016\/s2213-8587(25)00319-5"},{"issue":"4","key":"8237_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae016","volume":"8","author":"G Adami","year":"2024","unstructured":"Adami G, Pedrollo E, Rossini M et al (2024) Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR 8(4):ziae016. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae016","journal-title":"JBMR"},{"issue":"3","key":"8237_CR78","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","volume":"105","author":"D Kendler","year":"2020","unstructured":"Kendler D, Chines A, Clark P et al (2020) Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 105(3):e255\u2013e264. https:\/\/doi.org\/10.1210\/clinem\/dgz095","journal-title":"J Clin Endocrinol Metab"},{"key":"8237_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100290","volume":"13","author":"M Laroche","year":"2020","unstructured":"Laroche M, Couture G, Ruyssen-Witrand A, Constantin A, Degbo\u00e9 Y (2020) Effect of risedronate on bone loss at discontinuation of denosumab. Bone Rep 13:100290. https:\/\/doi.org\/10.1016\/j.bonr.2020.100290","journal-title":"Bone Rep"},{"issue":"12","key":"8237_CR80","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Min Res 34(12):2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Min Res"},{"issue":"6","key":"8237_CR81","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","volume":"38","author":"H Kondo","year":"2020","unstructured":"Kondo H, Okimoto N, Yoshioka T et al (2020) Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. J Bone Min Metab 38(6):894\u2013902. https:\/\/doi.org\/10.1007\/s00774-020-01126-w","journal-title":"J Bone Min Metab"},{"issue":"5","key":"8237_CR82","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/jbmr.4259","volume":"36","author":"SK Ramchand","year":"2021","unstructured":"Ramchand SK, David NL, Lee H, Eastell R, Tsai JN, Leder BZ (2021) Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD study extension. J Bone Miner Res 36(5):921\u2013930. https:\/\/doi.org\/10.1002\/jbmr.4259","journal-title":"J Bone Miner Res"},{"issue":"11","key":"8237_CR83","doi-asserted-by":"publisher","first-page":"e2443899","DOI":"10.1001\/jamanetworkopen.2024.43899","volume":"7","author":"C-C Lee","year":"2024","unstructured":"Lee C-C, Wang C-Y, Yen H-K et al (2024) Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial. JAMA Netw Open 7(11):e2443899. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43899","journal-title":"JAMA Netw Open"},{"issue":"1","key":"8237_CR84","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00223-025-01364-y","volume":"116","author":"NS Haeri","year":"2025","unstructured":"Haeri NS, Perera S, Greenspan SL (2025) Impact of zoledronic acid on bone mineral density and trabecular score following denosumab discontinuation in older adults in long-term care. Calcif Tissue Int 116(1):55. https:\/\/doi.org\/10.1007\/s00223-025-01364-y","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"8237_CR85","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial. J Bone Miner Res 34(12):2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Miner Res"},{"issue":"7","key":"8237_CR86","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Min Res 35(7):1207\u20131215. https:\/\/doi.org\/10.1002\/jbmr.3962","journal-title":"J Bone Min Res"},{"issue":"10","key":"8237_CR87","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE et al (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106(10):e4155\u2013e4162. https:\/\/doi.org\/10.1210\/clinem\/dgab321","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"8237_CR88","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Min Res 36(7):1245\u20131254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Min Res"},{"issue":"10","key":"8237_CR89","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Min Res 35(10):1858\u20131870. https:\/\/doi.org\/10.1002\/jbmr.4098","journal-title":"J Bone Min Res"},{"issue":"3","key":"8237_CR90","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","volume":"36","author":"N Laursen","year":"2025","unstructured":"Laursen N, S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2025) Clinical experience with denosumab discontinuation. Osteoporos Int 36(3):435\u2013446. https:\/\/doi.org\/10.1007\/s00198-024-07351-7","journal-title":"Osteoporos Int"},{"key":"8237_CR91","doi-asserted-by":"publisher","unstructured":"Grassi G, Ghielmetti A, Zampogna M, et al Zoledronate after denosumab discontinuation: Is repeated administrations more effective than single infusion? J Clin Endocrinol Metab https:\/\/doi.org\/10.1210\/clinem\/dgae224","DOI":"10.1210\/clinem\/dgae224"},{"issue":"7","key":"8237_CR92","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","volume":"33","author":"J Ha","year":"2022","unstructured":"Ha J, Kim J, Jeong C et al (2022) Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women. Osteoporos Int 33(7):1591\u20131599. https:\/\/doi.org\/10.1007\/s00198-022-06388-w","journal-title":"Osteoporos Int"},{"issue":"1","key":"8237_CR93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00223-022-00962-4","volume":"111","author":"N Hong","year":"2022","unstructured":"Hong N, Shin S, Lee S, Kim KJ, Rhee Y (2022) Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis. Calcif Tissue Int 111(1):47\u201355. https:\/\/doi.org\/10.1007\/s00223-022-00962-4","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"8237_CR94","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","volume":"80","author":"AA Khan","year":"2023","unstructured":"Khan AA, AbuAlrob H, M\u2019Hiri I et al (2023) Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60\u2009mg dose: a prospective observational study. Endocrine 80(3):647\u2013657. https:\/\/doi.org\/10.1007\/s12020-022-03230-5","journal-title":"Endocrine"},{"issue":"Supplement_1","key":"8237_CR95","doi-asserted-by":"publisher","first-page":"A190","DOI":"10.1210\/jendso\/bvac150.392","volume":"6","author":"Q Ibrahim","year":"2022","unstructured":"Ibrahim Q, Khan AA, Ali DS (2022) OR01-5 transition from low dose denosumab 30mg to IV zoledronic acid: effect on bone mineral density in postmenopausal women with osteoporosis: a prospective observational study. J Endocr Soc 6(Supplement_1):A190\u2013A190. https:\/\/doi.org\/10.1210\/jendso\/bvac150.392","journal-title":"J Endocr Soc"},{"issue":"7","key":"8237_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10731","volume":"7","author":"M Laroche","year":"2023","unstructured":"Laroche M, Couture G, Degbo\u00e9 Y (2023) Discontinuation of denosumab: gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine. JBMR 7(7):e10731. https:\/\/doi.org\/10.1002\/jbm4.10731","journal-title":"JBMR"},{"key":"8237_CR97","doi-asserted-by":"publisher","unstructured":"Effects on BMD and fracture incidence in patients switched to once a year denosumab after improvement in BMD from osteoporosis to osteopenia on standard dosing denosumab. Endocr Pract 31(9):S186\u2013S187. https:\/\/doi.org\/10.1016\/j.eprac.2025.05.519","DOI":"10.1016\/j.eprac.2025.05.519"},{"issue":"2","key":"8237_CR98","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","volume":"31","author":"K Ebina","year":"2021","unstructured":"Ebina K, Hashimoto J, Kashii M et al (2021) Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Mod Rheumatol 31(2):485\u2013492. https:\/\/doi.org\/10.1080\/14397595.2020.1769895","journal-title":"Mod Rheumatol"},{"key":"8237_CR99","doi-asserted-by":"publisher","unstructured":"Ha J, Jung KY, Kim KJ, Ahn SH, Kim H-J, Chung Y-S (2025) Effects of sequential anti-resorptive agents on bone mineral density following denosumab withdrawal: a multicenter real-world study in Korea (MAXCARE Study). J Korean Endocr Soc. https:\/\/doi.org\/10.3803\/EnM.2024.2227","DOI":"10.3803\/EnM.2024.2227"},{"issue":"3","key":"8237_CR100","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/eje-21-0157","volume":"185","author":"G Grassi","year":"2021","unstructured":"Grassi G, Chiodini I, Palmieri S, Cairoli E, Arosio M, Eller-Vainicher C (2021) Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence. Eur J Endocrinol 185(3):387\u2013396. https:\/\/doi.org\/10.1530\/eje-21-0157","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"8237_CR101","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1210\/clinem\/dgae240","volume":"110","author":"M Kamanda-Kosseh","year":"2024","unstructured":"Kamanda-Kosseh M, Shiau S, Agarwal S et al (2024) Bisphosphonates maintain BMD after sequential teriparatide and denosumab in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 110(3):e791\u2013e801. https:\/\/doi.org\/10.1210\/clinem\/dgae240","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"8237_CR102","doi-asserted-by":"publisher","first-page":"e3540","DOI":"10.1210\/clinem\/dgaa489","volume":"105","author":"A Cohen","year":"2020","unstructured":"Cohen A, Shiau S, Nair N et al (2020) Effect of teriparatide on bone remodeling and density in premenopausal idiopathic osteoporosis: a phase II trial. J Clin Endocrinol Metab 105(10):e3540\u2013e3556. https:\/\/doi.org\/10.1210\/clinem\/dgaa489","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"8237_CR103","doi-asserted-by":"publisher","first-page":"e1528","DOI":"10.1210\/clinem\/dgab850","volume":"107","author":"E Shane","year":"2021","unstructured":"Shane E, Shiau S, Recker RR et al (2021) Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 107(4):e1528\u2013e1540. https:\/\/doi.org\/10.1210\/clinem\/dgab850","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"8237_CR104","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","volume":"34","author":"T Tutaworn","year":"2023","unstructured":"Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM (2023) Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Osteoporos Int 34(3):573\u2013584. https:\/\/doi.org\/10.1007\/s00198-022-06648-9","journal-title":"Osteoporos Int"},{"key":"8237_CR105","doi-asserted-by":"publisher","unstructured":"Farias V, Jerkovich F, Barrag\u00e1n AM, et al (2024) Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study. JBMR Plus 8(6) https:\/\/doi.org\/10.1093\/jbmrpl\/ziae044","DOI":"10.1093\/jbmrpl\/ziae044"},{"issue":"2","key":"8237_CR106","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","volume":"35","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK, Tsai JN, Lee H et al (2024) The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial. Osteoporos Int 35(2):255\u2013263. https:\/\/doi.org\/10.1007\/s00198-023-06932-2","journal-title":"Osteoporos Int"},{"key":"8237_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115478","volume":"138","author":"P Makras","year":"2020","unstructured":"Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD (2020) The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone 138:115478. https:\/\/doi.org\/10.1016\/j.bone.2020.115478","journal-title":"Bone"},{"issue":"4","key":"8237_CR108","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00223-023-01119-7","volume":"113","author":"AD Anastasilakis","year":"2023","unstructured":"Anastasilakis AD, Makras P, Polyzos SA, Papapoulos SE (2023) The five-year effect of a single zoledronate infusion on bone mineral density following denosumab discontinuation in women with postmenopausal osteoporosis. Calcif Tissue Int 113(4):469\u2013473. https:\/\/doi.org\/10.1007\/s00223-023-01119-7","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"8237_CR109","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00198-024-07213-2","volume":"35","author":"JN Tsai","year":"2024","unstructured":"Tsai JN, Jordan M, Lee H, Leder BZ (2024) One versus 2 years of alendronate following denosumab: the CARD extension. Osteoporos Int 35(12):2225\u20132230. https:\/\/doi.org\/10.1007\/s00198-024-07213-2","journal-title":"Osteoporos Int"},{"key":"8237_CR110","doi-asserted-by":"publisher","unstructured":"Ferrari S, Hars M, Biver E, et al (2026) Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates. Osteoporosis Int https:\/\/doi.org\/10.1007\/s00198-026-08115-1","DOI":"10.1007\/s00198-026-08115-1"},{"key":"8237_CR111","doi-asserted-by":"publisher","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O, Group at SDS (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36(9):1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335","DOI":"10.1002\/jbmr.4335"},{"key":"8237_CR112","doi-asserted-by":"publisher","unstructured":"Japelj M, Vidmar G, Rajic A, Pfeifer M, Kocjan T (2018) Bone mineral density decline following denosumab discontinuation might not be attenuated with previous bisphosphonate therapy. Endocr Abstracts. https:\/\/doi.org\/10.1530\/endoabs.56.P188","DOI":"10.1530\/endoabs.56.P188"},{"issue":"8","key":"8237_CR113","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33(8):1397\u20131406. https:\/\/doi.org\/10.1002\/jbmr.3452","journal-title":"J Bone Miner Res"},{"issue":"8","key":"8237_CR114","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/jc.2008-2630","volume":"94","author":"BZ Leder","year":"2009","unstructured":"Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94(8):2915\u20132921. https:\/\/doi.org\/10.1210\/jc.2008-2630","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"8237_CR115","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Jama 296(24):2927\u20132938. https:\/\/doi.org\/10.1001\/jama.296.24.2927","journal-title":"Jama"},{"issue":"2","key":"8237_CR116","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(2):243\u2013254. https:\/\/doi.org\/10.1002\/jbmr.1494","journal-title":"J Bone Miner Res"},{"issue":"5","key":"8237_CR117","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19(5):307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"key":"8237_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116498","volume":"163","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Reichenbach S, Gahl B et al (2022) Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting. Bone 163:116498. https:\/\/doi.org\/10.1016\/j.bone.2022.116498","journal-title":"Bone"},{"issue":"9","key":"8237_CR119","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"Uebelhart B, Rizzoli R, Ferrari SL (2017) Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int 28(9):2701\u20132705. https:\/\/doi.org\/10.1007\/s00198-017-4080-6","journal-title":"Osteoporos Int"},{"key":"8237_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116764","volume":"172","author":"G Liebich","year":"2023","unstructured":"Liebich G, Lamy O, Aubry-Rozier B, Gonzalez-Rodriguez E (2023) Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study. Bone 172:116764. https:\/\/doi.org\/10.1016\/j.bone.2023.116764","journal-title":"Bone"},{"issue":"9","key":"8237_CR121","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbj\u00e6rg CS, Langdahl BL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161\u20133169. https:\/\/doi.org\/10.1210\/jc.2012-1569","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"8237_CR122","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.afos.2017.03.003","volume":"3","author":"T Suzuki","year":"2017","unstructured":"Suzuki T, Nakamura Y, Kamimura M, Ikegami S, Uchiyama S, Kato H (2017) Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis. Osteoporosis Sarcopenia 3(2):108\u2013111. https:\/\/doi.org\/10.1016\/j.afos.2017.03.003","journal-title":"Osteoporosis Sarcopenia"},{"issue":"6","key":"8237_CR123","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.injury.2020.11.041","volume":"52","author":"S-J Kim","year":"2021","unstructured":"Kim S-J, Cho YJ, Lee D-W (2021) Patients\u2019 first-year adherence to different anti-osteoporotic therapy after hip fractures. Injury 52(6):1506\u20131510. https:\/\/doi.org\/10.1016\/j.injury.2020.11.041","journal-title":"Injury"},{"issue":"2","key":"8237_CR124","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3803\/EnM.2023.1663","volume":"38","author":"C Jeong","year":"2023","unstructured":"Jeong C, Lee J, Kim J et al (2023) Persistence with denosumab in male osteoporosis patients: a real-world, non-interventional multicenter study. Endocrinol Metab 38(2):260\u2013268. https:\/\/doi.org\/10.3803\/EnM.2023.1663","journal-title":"Endocrinol Metab"},{"issue":"1","key":"8237_CR125","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporosis Int 23(1):317\u2013326. https:\/\/doi.org\/10.1007\/s00198-011-1780-1","journal-title":"Osteoporosis Int"},{"issue":"10","key":"8237_CR126","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/s2213-8587(19)30255-4","volume":"7","author":"JN Tsai","year":"2019","unstructured":"Tsai JN, Lee H, David NL, Eastell R, Leder BZ (2019) Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol 7(10):767\u2013775. https:\/\/doi.org\/10.1016\/s2213-8587(19)30255-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"8237_CR127","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08237-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08237-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08237-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:03:01Z","timestamp":1790974981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08237-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":127,"alternative-id":["8237"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08237-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is not applicable as it is a systematic review of publicly available data.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NL declares no conflict of interest. ASS has received lecture fees from Amgen and UCB. TH has received speaker fees from UCB, Amgen, AstraZeneca, and Astellas Pharma. BL has received honoraria for advisory board and lecture engagements from UCB, Amgen, Gedeon Richter, Mereo, Angitia, Sandoz, Entera-Bio, and Samsung Bioepis.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}